CD8A and cancer: Our findings reveal that bryostatin-1 reinvigorates exhausted CD8+ T cells and expands HIV-specific CD8+ T cells, suggesting that byrostatin-1 may be beneficial in the treatment of HIV infection and may also improve immunotherapy in cancers.